Editas Medicine (EDIT)

$39.85 0.99 (2.42%)

16:00 EDT EDIT Stock Quote Delayed 30 Minutes

Editas Stock Isn’t Worth Buying This Early Into Treatment Development

By Alex Sirois Jul 21, 2021

EDIT stock is part of a pioneering movement in CRISPR gene editing, but there's no way to know whether the company will succeed long term.

The Top 3 Gene Editing Stocks to Own for the Next Decade

The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century

Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar

More Articles

Volume:

Previous Close -

Market Cap 2.70B

PE Ratio -11.52

EPS -3.46

Volume (Avg. Vol.) 1.02M

Day's Range 39.50 - 41.95

52-Week Range 27.01 - 99.95

Dividend & Yield N/A (N/A)

EDIT Stock Predictions, Articles, and Editas Medicine News

From InvestorPlace
From the Web

Midday Market Update: 10 Biggest Stock Gainers Today

By William White, InvestorPlace Writer Jun 30, 2021

Good afternoon, investors! We're taking a look at how the market is doing halfway through the day with a midday market update.

What Will the Stock Market Do Today? 3 Big Stories to Watch.

By Sarah Smith, Editor, Today's Market Jun 28, 2021

So what will the stock market do today? All eyes are on gene-editing stocks like NTLA and on recovering crypto prices.

Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks

By Robert Lakin, InvestorPlace Contributor Jun 28, 2021

Gene editing stocks are getting a boost on Monday morning after Intellia Therapeutics said it was successful using CRISPR gene-editing therapy directed inside the body to an internal organ.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Jun 28, 2021

Good morning! Let's get ready for trading to start off strong this week with a look at the biggest pre-market stock movers for Monday!

7 Stocks to Buy for May

By Tezcan Gecgil, InvestorPlace Contributor Apr 27, 2021

Broader markets be at all-time highs, but there are still opportunities for the coming months. Here are seven stocks to buy this May.

What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

By Sarah Smith, Editor, Today's Market Apr 16, 2021

So what did the stock market do today? Dogecoin prices and other cryptocurrencies stole the show, and CRISPR stocks sold off.

CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today

By Vivian Medithi Apr 16, 2021

A "sell" rating is one thing, but a price target barely half of the Thursday close? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.

Goldman Sachs Just Put Editas Stock on Sale — Buy the Dip

By Luke Lango, InvestorPlace Senior Investment Analyst Apr 16, 2021

Goldman says Editas' clinical data may underwhelm. We don't agree. So this is the time to buy the dip in EDIT stock.

Investing in CRISPR Stocks: Ultimate Genetic Editing Guide

By Luke Lango, InvestorPlace Senior Investment Analyst Apr 15, 2021

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.

Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today

By William White, InvestorPlace Writer Mar 10, 2021

Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players.

A Play on the Biggest Scientific Breakthrough of the Century

By Luke Lango, InvestorPlace Senior Investment Analyst Jan 22, 2021

There are only a handful of large, well-established gene editors with robust and mature therapy pipelines in the world today. Of those, one that stands out is a $4.8 billion biotechnology company by the name of Editas Medicine (NASDAQ:EDIT).

7 CRISPR Stocks for the Future of Medicine

By Luke Lango, InvestorPlace Senior Investment Analyst Jan 15, 2021

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century.

Editas Medicine: 6 Things for Potential EDIT Stock Investors to Know Today

By William White, InvestorPlace Writer Dec 21, 2020

Editas Medicine (EDIT) stock is soaring higher on Monday with heavy trading despite a lack of recent news from the gene-editing company.

5 Disruptive Biotech Stocks to Buy for the Future That Is Here

By Alex Sirois Aug 13, 2020

Biotech stocks are futuristic, but they're also bearing fruit now. So, check out these five hitting on trends and making investors money now.

7 Biotech Stocks to Buy and Hold in 2020

By Chris Lau, InvestorPlace Contributor Mar 16, 2020

Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.

The Top 3 Gene-Editing Stocks to Own in 2020

By Ian Cooper Mar 11, 2020

The gene-editing revolution is already here, and could be a sizable boon for investors in three of the sector's top stocks.

3 Biotech Stocks That Are Set for a Breakthrough

By InvestorPlace Research Staff Feb 1, 2019

If you're looking for biotech stocks to buy with massive breakthrough potential in gene editing, then these three are kings among the rest.

Gene Editing is a Major Technology to Watch

By InvestorPlace Research Staff Aug 27, 2018

Gene-editing technology is going to be a game-changer in the future, which means the time to invest in CRISPR stocks is now.

Whole Foods Market, Inc. (WFM) and Xtant Medical Holdings Inc (XTNT) Lead 13 Activist Investment Filings

By Fintel May 31, 2017

13G and 13D filings are windows into activist investor activity. Latest filings include Whole Foods Markets, Inc., and these 12 other stocks

Editas Medicine Stock Shows Improved Relative Strength Rating

From Investor's Business Daily Jul 22, 2021

A Relative Strength Rating upgrade for Editas Medicine shows improving technical performance. Will it continue?

Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week

From The Motley Fool Jul 16, 2021

After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.

After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding

From The Motley Fool Jul 15, 2021

It's a good time to be a gene-editing company.

WHO Issues Framework For Governance For Gene Editing Technologies

From Benzinga Jul 12, 2021

A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or...

What Are The Best Stocks To Invest In? 5 Gene Editing Stocks To Watch Now

From StockMarket.com Jul 12, 2021

There exciting developments from gene-editing companies are sending bullish waves across the space.

A Comprehensive Guide To Genomic ETFs

From Talk Markets Jul 11, 2021

Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon make genomics the next big thing in the space.